BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Iborra M, García-Morales N, Rubio S, Bertoletti F, Calvo M, Taxonera C, Boscá-Watts MM, Sierra M, Mancenido N, Beltrán B, Nantes Castillejo Ó, García-Planella E, Vera I, Alba C, Martí-Aguado D, Ballester MP, Cano-Sanz N, Pajares-Villarroya R, Cerrillo E, Cañada A, Nos P. Real-life experience with 4 years of golimumab persistence in ulcerative colitis patients. Sci Rep 2020;10:17774. [PMID: 33082359 DOI: 10.1038/s41598-020-73577-0] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Barbieri MA, Viola A, Cicala G, Spina E, Fries W. Effectiveness and Safety Profiles of Biological Therapies in Inflammatory Bowel Disease: Real Life Data from an Active Pharmacovigilance Project. Biomedicines 2022;10. [PMID: 36552036 DOI: 10.3390/biomedicines10123280] [Reference Citation Analysis]
2 Cassinotti A, Mezzina N, De Silvestri A, Di Paolo D, Lenti MV, Bezzio C, Stradella D, Mauri M, Zadro V, Ricci C, Casini V, Radice E, Massari A, Maconi G, Saibeni S, Caprioli F, Tari R, Fichera M, Cortelezzi CC, Parravicini M, Tinelli C, Testoni PA, Pace F, Segato S, Invernizzi P, Occhipinti P, Manes G, Di Sabatino A, Pastorelli L, Vecchi M, Ardizzone S. Continuous clinical remission with biologics in ulcerative colitis: the 'AURORA' comparison study. Eur J Gastroenterol Hepatol 2022;34:1238-46. [PMID: 36165081 DOI: 10.1097/MEG.0000000000002443] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Cui G, Florholmen J, Goll R. Could Mucosal TNF Transcript as a Biomarker Candidate Help Optimize Anti-TNF Biological Therapy in Patients With Ulcerative Colitis? Front Immunol 2022;13:881112. [PMID: 35663996 DOI: 10.3389/fimmu.2022.881112] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Ferrante M, Schirbel A, Pierik MJ, Haas T, Flamant M, Khalifa A, Philip G, Cornillie F, Meehan AG, Govoni M. Patient-reported continuous clinical response to golimumab in adults with moderately to severely active ulcerative colitis: results from GO OBSERVE, a real-world European observational study. Eur J Gastroenterol Hepatol 2022;34:646-54. [PMID: 35412484 DOI: 10.1097/MEG.0000000000002374] [Reference Citation Analysis]
5 Ylisaukko-Oja T, Puttonen M, Jokelainen J, Koivusalo M, Tamminen K, Torvinen S, Voutilainen M. Dose-escalation of adalimumab, golimumab or ustekinumab in inflammatory bowel diseases: characterization and implications in real-life clinical practice. Scand J Gastroenterol 2022;57:415-23. [PMID: 34927504 DOI: 10.1080/00365521.2021.2014950] [Reference Citation Analysis]
6 Perrig K, Krupka N, Jordi SBU, Rossel J, Biedermann L, Greuter T, Schreiner P, Vavricka SR, Juillerat P, Burri E, Zimmermann D, Maillard MH, Sulz MC, Brand S, Rogler G, Misselwitz B. Effectiveness of golimumab in patients with ulcerative colitis: results of a real-life study in Switzerland. Therap Adv Gastroenterol 2022;15:175628482210741. [DOI: 10.1177/17562848221074188] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
7 Tursi A. Performances of anti-TNFα antibodies as long-term maintenance therapy for ulcerative colitis. Eur J Gastroenterol Hepatol 2021;33:e1107-8. [PMID: 35048684 DOI: 10.1097/MEG.0000000000002220] [Reference Citation Analysis]